Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | CASP1 | P29466 | 2/20 | 0.59 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | PYGM | P11217 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29820118 | 1.00 | RAB9A (1.00) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL29101820 | 0.88 | KDM4E (0.78) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL30637057 | 0.88 | KDM4E (0.78) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL28362353 | 0.86 | KDM4E (1.00) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL31448344 | 0.86 | KDM4E (1.00) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL28365990 | 0.86 | KDM4E (0.76) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL12794447 | 0.86 | RAB9A (0.76) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL30637061 | 0.86 | KDM4E (0.76) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL2630604 | 0.85 | RAB9A (0.74) | RAB9AKDM4ENPC1HSD17B10CASP1 | |
| SCHEMBL30637056 | 0.83 | KDM4E (0.71) | RAB9AKDM4ENPC1HSD17B10CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4181724-A | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | claimed |
| US-20260103446-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4019501-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12503447-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-23 | — | — | US | disclosed |
| US-12391654-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-19 | — | — | US | disclosed |
| CN-116143751-B | Quinoxalinone compound containing styrylpyridine and preparation method thereof | 中国人民解放军军事科学院防化研究院 | 2025-07-15 | — | — | CN | disclosed |
| US-20250109113-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-03 | — | — | US | disclosed |
| US-12187694-B2 | SLC26A3 inhibitors and use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-07 | — | — | US | disclosed |
| US-12065412-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4071140-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2024-07-03 | — | — | EP | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1615613-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004093798-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093798-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20030207886-A1 | Preparation containing quinoxaline derivatives | MERCK PATENT GMBH (DE) | 2003-11-06 | — | — | US | disclosed |
| US-5597922-A | Glycine receptor antagonist pharmacophore | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1997-01-28 | — | — | US | disclosed |
| WO-1996004288-A1 | GLYCINE RECEPTOR ANTAGONIST PHARMACOPHORE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, CTSC | RAB9A 2677/4885KDM4E 856/4885NPC1 368/4885 |
| US-12187694-B2 | SLC26A3 inhibitors and use thereof | SLC26A3, SLC10A2, ORAI3 | RAB9A 2807/4885KDM4E 4836/4885NPC1 1326/4885 |
| US-12065412-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | RAB9A 1086/4885KDM4E 4709/4885NPC1 579/4885 |
| US-12391654-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | RAB9A 1086/4885KDM4E 4709/4885NPC1 579/4885 |
| US-20260103446-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, CLCN2, SLC26A3 | RAB9A 3079/4885KDM4E 4660/4885NPC1 402/4885 |
| US-12503447-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | RAB9A 1086/4885KDM4E 4709/4885NPC1 579/4885 |
| US-20030207886-A1 | Preparation containing quinoxaline derivatives | CUTA, XPA, NQO2 | RAB9A 989/4885KDM4E 467/4885NPC1 4650/4885 |
| US-20250109113-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | RAB9A 1086/4885KDM4E 4709/4885NPC1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.